Open Access Articles- Top Results for Ofatumumab


Monoclonal antibody
Type Whole antibody
Source Human
Target CD20
Clinical data
Trade names Arzerra
AHFS/ monograph
MedlinePlus a610009
Licence data EMA:Link, US FDA:link
  • US: C (Risk not ruled out)
Pharmacokinetic data
Half-life 14 days
679818-59-8 7pxN
UNII M95KG522R0 7pxY
ChEMBL CHEMBL1201836 7pxN
Chemical data
Formula C6480H10022N1742O2020S44
146.1 kDa
 14pxN (what is this?)  (verify)

Ofatumumab[1] (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin’s lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia. This makes ofatumumab the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.

Medical uses

Its only indication that has received regulatory approval is Chronic lymphocytic leukaemia (CLL).[2][3][4]

FDA Approval

It first received FDA approval on April 17, 2014, for use in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate[2] MHRA approval on the 19th of April 2010,[4]

EMA Approval

EMA approval on the 14th of June 2010[3] and Health Canada approval on the 13th of August 2012.[5]

Adverse effects

Adverse effects by frequency:[2][3][4]
Very common (>10% frequency):

Common (1-10% frequency):'

  • Sepsis
  • Herpes virus infection
  • Urinary tract infection
  • Febrile neutropenia
  • Leucopenia
  • Thrombocytopenia
  • Anaphylactoid reactions
  • Hypersensitivity
  • Tachycardia
  • Hypotension
  • Hypertension
  • Bronchospasm
  • Hypoxia
  • Dyspnoea (shortness of breath)
  • Chest discomfort
  • Pharyngolaryngeal pain
  • Cough
  • Nasal congestion
  • Small bowel obstruction
  • Diarrhoea
  • Nausea
  • Urticaria (hives)
  • Itchiness
  • Flushing
  • Back pain
  • Cytokine release syndrome
  • Pyrexia (fever)
  • Rigors
  • Chills
  • Hyperhidrosis
  • Fatigue

Uncommon (0.1-1% frequency):

Rare (<0.1% frequency):

Ofatumumab has received a black box warning regarding the potential for it to cause progressive multifocal leukoencephalopathy and Hepatitis B reactivation.[6] Likewise it is also advised that doctors watch cautiously for small bowel obstruction, neutropenia, thrombocytopenia, infusion reactions or an increased risk for infection.[6]


It is contraindicated in individuals that have hypersensitivity to ofatumumab or any of its excipients.[4]


No formal drug interaction studies have been conducted with ofatumumab.[2] Although it is advised that patients are not administered live virus vaccines (e.g. the oral polio vaccine) while undergoing treatment with ofatumumab due to the compromised ability to fight the attenuated viruses seen in patients being treated with ofatumumab.[6]


Ofatumumab is a humanised anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab.[7] The CD20 antigen is expressed on solely B cell lymphocytes.[7] Compared with rituximab, ofatumumab binds more tightly to CD20 with a slower off-rate.[7] It causes cytotoxicity in the cells that express CD20 by means of complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC).[7]

Clinical trials

Status of clinical trials of ofatumumab conducted by Genmab and GSK, as of late 2010.

See also


  1. ^ Zhang, Bodi (2009). "Ofatumumab". MAbs 1 (4): 326–331. PMC 2726602. PMID 20068404. doi:10.4161/mabs.1.4.8895. 
  2. ^ a b c d "ARZERRA (ofatumumab) injection, solution [GlaxoSmithKline LLC]". DailyMed. GlaxoSmithKline LLC. September 2013. Retrieved 24 January 2014. 
  3. ^ a b c "Arzerra : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 7 March 2013. Retrieved 24 January 2014. 
  4. ^ a b c d "Arzerra (acetate formulation) -Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 27 November 2013. Retrieved 24 January 2014. 
  5. ^ "Product Information". Health Canada. GlaxoSmithKline Inc. 13 August 2012. 
  6. ^ a b c "Arzerra (ofatumumab) dosing, indications, interactions, and more". Medscape Reference. WebMD. Retrieved 24 January 2014. 
  7. ^ a b c d Lin, TS (2010). "Ofatumumab: a novel monoclonal anti-CD20 antibody" (PDF). Pharmacogenomics and personalized medicine 3: 51–59. PMC 3513208. PMID 23226042. 
  8. ^
  9. ^ Clinical trial number NCT00611455 for "Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to MTX Therapy" at
  10. ^ Clinical trial number NCT00603525 for "Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy" at
  11. ^ Clinical trial number NCTNCT01014208 for "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma (ORCHARRD" at
  12. ^ Clinical trial number NCT00349349 for "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab" at
  13. ^
  14. ^